*** Angle Plc. What have they got going for them? ***16 Nov 2023 10:03
They have worldwide patents on their parsortix machine.
A machine that can separate out a single circulating cancer cell (cct) from a standard blood sample.
This enables a cancer that has matastacised (spread) to be analysed/tested from a simple standard blood test. The results give UP TO DATE valuable information about a persons cancer. Often a matastacised cancer cannot be analysed/tested because the original tumour was cut out months/years earlier and a cancer CHANGES OVER TIME. This makes the results of the original test UNRELIABLE and could result in the WRONG TREATMENT being selected.
****The issue has been how to monetize this technology****.
It's been 7 months since Angle announced the contract with Bioview to develop the HER2 assay and that as far as I can see could be a massive money spinner. This gives me confidence as obviously the Directors of Bioview Ltd would not invest £1.2 million of their money unless they expect a very good return would they? The HER2 status of breast cancer is a prime example of how the parsortix machine can help select the appropriate treatment. The HER2 status of breast cancer can change over time. A different status (positive or negative) is important in treatment selection. If the HER2 status of a persons cancer has changed since the original biopsy the WRONG treatment might be selected. Being able to do an UP TO DATE test is clearly vital to ensure the correct treatment is selected.
The PD-L1 assay, announced just the other day is now available. I think this is another potential big money spinner.
PD-L1 is an immune-related biomarker that can be on the surface of tumour cells across a range of cancer types, and this biomarker enables cancer cells to evade a persons immune response mechanisms. Some immunotherapy Companies use PD-1/PD-L1 inhibitors to stop the cancer cells from beng able to evade a persons immune response which would otherwise kill the cancer cell.
The Companies that sell these therapies have a big problem in that they are often unable to test the PD-L1 status of a patient just before and during treatment. Once again the reason being these cancers can change over time and the original biopsy may have been done months or years before and cannot be done again. They need to have this ability during their immunotherapy trials to gather valuable data. From a test just before treatment they would be able to find out the levels of PD-1/PD-L1 in cancers that responded best. Then during treatment monitor these levels to get an early indication whether the treatment is working. Finally this data could be used to target people best suited to the treatment and in time Angle's assay could be used for patient selection, a potentially massive market.
A sample of what lies ahead I believe.
All IMHO. Do your own research.
Sign In
Follow the stocks
